BioCurity Pharmaceuticals Inc.

BioCurity is a clinical stage biopharmaceutical company. Its mission is to improve radiation therapy for cancer patients.

The company’s proprietary technology is designed to prevent or mitigate damage to skin and normal tissue during radiation, without impairing the effectiveness of the treatment on cancer cells.

The proposed drugs generated from BioCurity’s technology, which are delivered via a skin topical and an IV, have been pre-clinically tested for multiple cancers, including breast, lung, prostate, and colorectal.

BioCurity has been issued seven patents for its technology, and its team has done more than 20 years of cancer treatment research.

The company is seeking capital to begin plans to submit a Pre-Investigational New Drug Application with the FDA.

Team Background

Nancy Cass - Director

Sam Merchant - Chairman of the Board

Dr. Cheryl Baker - Chief Scientific Research Officer

Co-Investors